A 52-year-old female patient with unstable angina pectoris was prescribed enteric-coated aspirin tablets (100 mg once daily), ticagrelor tablets (90 mg twice daily), metoprolol succinate sustained-release tablets (23.75 mg once daily), nicorandil tablets (5 mg three times daily), and rosuvastatin calcium tablets (10 mg once daily) following coronary intervention. Three days later, the patient developed ptosis of the left eyelid, difficulty in opening the eye, diplopia, limited adduction of the left eye, and impaired upward gaze of both eyes. The patient was successively treated with pranoprofen eye drops, escin and digitalis glycosides eye drops, pancreatic kininogenase enteric-coated tablets, and mecobalamin tablets, but no relief was achieved. Further examination in the neurology department showed a positive neostigmine test. Electromyography showed decremental responses in the low-frequency range during repetitive nerve stimulation of the left facial nerve (recording orbicularis oculi muscle), left axillary nerve, and right femoral nerve, leading to a diagnosis of ocular myasthenia gravis (OMG). Rosuvastatin was discontinued immediately and replaced with ezetimibe (10 mg, once daily) and the patient's symptoms improved significantly after 43 days. The association between OMG and rosuvastatin was assessed using Naranjo's Assessment Scale, and the result was "probable". This case highlights the need for clinical vigilance regarding the rare adverse drug reaction of statin-induced OMG to ensure patient medication safety.

1. PazML, BarrantesFJ. Cholesterol in myasthenia gravis[J]. Arch Biochem Biophys, 2021, 701: 108788. DOI: 10.1016/j.abb. 2021. 108788.

2. ChenJ, TianDC, ZhangC, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study[J]. Lancet Reg Health West Pac, 2020, 5: 100063. DOI: 10.1016/j.lanwpc. 2020.100063.

3. 中国罕见病联盟神经罕见病专业委员会, 中国罕见病联盟重症肌无力协作组, 中华医学会神经病学分会神经肌肉病学组. 中国难治性全身型重症肌无力诊断和治疗专家共识(2024版)[J]. 中华神经科杂志, 2024, 57(8): 840-847.Neurology Society of China Alliance for Rare Diseases, Chinese Myasthenia Gravis Collaboration Group, Chinese Society of Neuromuscular Disease, Chinese Society of Neurology, Chinese Medical Association. Chinese expert consensus for diagnosis and treatment of refractory generalized myasthenia gravis (2024)[J]. Chinese Journal of Neurology, 2024, 57(8): 840-847. DOI: 10.3760/cma.j.cn113694-20240222-00106.

4. TsuiL, YeP, XuS, et al. Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis[J]. Eur J Hosp Pharm, 2023, 30(e1): e82-e89. DOI: 10.1136/ejhpharm-2022-003333.

5. 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3): 221-255.Joint Committee on Guideline for Lipid Management in China. Chinese guideline for lipid management (2023)[J]. Chinese Journal of Cardiology, 2023, 51(3): 221-255. DOI: 10.3760/cma.j.cn112148-20230119-00038.

6. ParmarB, FrancisPJ, RaggeNK. Statins, fibrates, and ocular myasthenia[J]. Lancet, 2002, 360(9334): 717. DOI: 10.1016/S0140-6736(02)09846-X.

7. XuW, YanVKC, ZhangZ, et al. Myasthenia gravis following statin therapy: evidence from target trial emulation and self-controlled case series study[J]. Nat Commun, 2024, 15(1): 10317. DOI: 10.1038/s41467-024-54097-1.

8. 中国免疫学会神经免疫分会. 中国重症肌无力诊断和治疗指南(2020版)[J]. 中国神经免疫学和神经病学杂志, 2021, 28(1): 1-12.Neuroimmunology Branch of Chinese Society of Immunology. Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 edition)[J]. Chinese Journal of Neuroimmunology and Neurology, 2021, 28(1): 1-12. DOI: 10.3969/j.issn.1006-2963.2021.01.001.

9. MiernikS, MatusiewiczA, OlesińskaM. Drug-induced myopathies: a comprehensive review and update[J]. Biomedicines, 2024, 12(5): 987. DOI: 10.3390/biomedicines12050987.

10. MurayamaH, SakumaM, TakahashiY, et al. Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study[J]. Pharmacol Res Perspect, 2018, 6(1): e00373.DOI: 10.1002/prp2.373.

11. SheikhS, AlviU, SolivenB, et al. Drugs that induce or cause deterioration of myasthenia gravis: an update[J]. J Clin Med, 2021, 10(7): 1537. DOI: 10.3390/jcm10071537.

12. OhSJ, DhallR, YoungA, et al. Statins may aggravate myasthenia gravis[J]. Muscle Nerve, 2008, 38(3): 1101-1107. DOI: 10.1002/mus.21074.

13. Gras-ChampelV, MasmoudiI, BatteuxB, et al. Statin-associated myasthenia: a case report and literature review[J]. Therapie, 2020, 75(3): 301-309. DOI: 10.1016/j.therap.2019.07.004.

14. PazML, BarrantesFJ. Cholesterol in myasthenia gravis[J]. Arch Biochem Biophys, 2021, 701: 108788. DOI: 10.1016/j.abb. 2021. 108788.

15. 姚明, 康吉云, 李昊洋, 等. 我国药学监护领域研究现状及趋势的可视化分析[J]. 数理医药学杂志, 2025, 38(1): 16-26.YaoM,KangJY,LiHY,et al. Visual analysis of the current research status and trends in the field of pharmaceutical care in China[J]. Journal of Mathematical Medicine, 2025, 38(1): 16-26. DOI: 10.12173/j.issn.1004-4337.202409024.

16. WilkeRA, LinDW, RodenDM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges[J]. Nat Rev Drug Discov, 2007, 6(11): 904-916. DOI: 10.1038/nrd2423.

17. LinkE, ParishS, ArmitageJ, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study[J]. N Engl J Med, 2008, 359(8): 789-799. DOI: 10.1056/NEJMoa0801936.

18. NguyenKA, LiL, LuD, et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy[J]. Eur J Clin Pharmacol, 2018, 74: 1099-1109. DOI: 10.1007/s00228-018-2482-9.

19. SugimotoT, SuzukiS, UzawaA, et al. Worsening of myasthenic symptoms associated with statins[J]. J Neurol Sci, 2024, 464: 123154. DOI: 10.1016/j.jns.2024.123154.

20. MarriottM, SchweryA, VandenBergA. Myasthenia gravis: what does a pharmacist need to know?[J]. Am J Health Syst Pharm, 2023, 80(5): 249-257. DOI: 10.1093/ajhp/zxac343.